Shield Therapeutics plc
SHIEF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.08 | 0.05 | 0.02 | -0.03 |
| FCF Yield | 15.00% | -4.44% | -10.48% | -14.54% |
| EV / EBITDA | -14.19 | -14.68 | -4.78 | 0.00 |
| Quality | ||||
| ROIC | -35.19% | -13.90% | -34.33% | 0.00% |
| Gross Margin | 49.36% | 47.25% | 44.98% | 20.32% |
| Cash Conversion Ratio | -0.87 | 0.27 | 0.23 | 0.83 |
| Growth | ||||
| Revenue 3-Year CAGR | 52.01% | 16.69% | -15.72% | -8.00% |
| Free Cash Flow Growth | 601.80% | 15.92% | 79.88% | 12.90% |
| Safety | ||||
| Net Debt / EBITDA | -4.09 | -6.22 | -2.23 | 0.00 |
| Interest Coverage | -1.61 | -4.03 | -9.89 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 1.17 | 0.70 | 0.83 | 0.00 |
| Cash Conversion Cycle | 30.11 | 250.91 | -180.08 | 0.00 |